Stockscreener 앱 받기
295.50
0.66%
-1.95
시간 외 거래:
296.00
0.50
+0.17%
Alnylam Pharmaceuticals Inc 주식(ALNY)의 최신 뉴스
Citi Initiates Alnylam (ALNY) With Buy Rating - Insider Monkey
Alnylam Pharmaceuticals Q3 2025 Earnings Preview - MSN
Alnylam Pharmaceuticals, Inc. (ALNY) Stock Analysis: A 49.88% Potential Upside for Biotech Investors - DirectorsTalk Interviews
Assessing Alnylam Pharmaceuticals (ALNY) Valuation After Mixed Share Performance And Strong AMVUTTRA Uptake - simplywall.st
Director at Alnylam (NASDAQ: ALNY) granted RSUs and stock options - Stock Titan
Alnylam (NASDAQ: ALNY) awards RSUs and options to board director - Stock Titan
Director at Alnylam (NASDAQ: ALNY) receives RSUs and options - Stock Titan
Alnylam (ALNY) director gets new RSUs, options and reports trust holdings - Stock Titan
Director Peter Kellogg granted RSUs and stock options at Alnylam (NASDAQ: ALNY) - Stock Titan
ALNY (ALNY) director granted 671 RSUs and 1,441 options at $298.48 - Stock Titan
Alnylam (ALNY) director Olivier Brandicourt receives new RSU and option grants - Stock Titan
ALNY (ALNY) director Dennis Ausiello granted RSUs and stock options awards - Stock Titan
Alnylam (ALNY) director granted RSUs and stock options in new equity awards - Stock Titan
Discipline and Rules-Based Execution in ALNY Response - Stock Traders Daily
Alnylam Pharmaceuticals (ALNY) 10K Form and Latest SEC Filings 2026 - MarketBeat
Ionis, Alnylam, BioMarin up as Citi starts at buy on catalyst and growth outlook - MSN
Alnylam Pharmaceuticals’ SWOT analysis: stock faces margin pressure By Investing.com - Investing.com South Africa
Alnylam Pharmaceuticals’ SWOT analysis: stock faces margin pressure - Investing.com
Alnylam Q1 Earnings Beat Estimates, Amvuttra Sales Drive Y/Y Growth - Eastern Progress
Alnylam Pharmaceuticals Inc Annual Shareholders Meeting Transcript - GuruFocus
ALNY Technical Analysis & Stock Price Forecast - Intellectia AI
ALNY Initiated Coverage by Citigroup -- Price Target Set at $380 - GuruFocus
Citi Initiates Coverage on Biotech Stocks: Ionis (IONS), Alnylam (ALNY), BioMarin (BMRN) - GuruFocus
Ionis, Alnylam, BioMarin are new Buys at Citi (ALNY:NASDAQ) - Seeking Alpha
Alnylam Issues 2025 Corporate Responsibility Report - BioSpace
Alnylam commits $2M to frontline care navigators in Boston - Stock Titan
How HELIOS-B Phase 3 Vutrisiran Data and Real-World Evidence Expansion Will Impact Alnylam (ALNY) Investors - simplywall.st
Immunic appoints Biogen, Cubist veteran Mike Bonney as board chair ahead of key MS trial readout - Proactive financial news
Citigroup initiates coverage of Alnylam Pharmaceuticals (ALNY) with buy recommendation - MSN
Daily Brief Health Care: Dermavon Holdings, Alebund Pharmaceuticals Jiangsu, Alnylam Pharmaceuticals, Artrya , Bavarian Nordic A/S, Cardinal Health, Dexcom Inc, American Shared Hospital Servi, Eli Lilly & Co, Abeona Therapeutics and more - Smartkarma
Protein Synthesis Research Market to Reach $42.8 Billion by 2031, Driven by Surging CGT Investment - GlobeNewswire Inc.
How Investors Are Reacting To Alnylam Pharmaceuticals (ALNY) New HELIOS-B Vutrisiran Data And Real-World Study - Yahoo Finance
Alnylam Pharmaceuticals, Inc. $ALNY Shares Bought by iA Global Asset Management Inc. - MarketBeat
Alnylam’s Vutrisiran Data And Real-World Study Contrast With Depressed Valuation - Yahoo Finance
Alnylam Pharmaceuticals, Inc. $ALNY Position Reduced by DNB Asset Management AS - MarketBeat
Is the options market predicting a spike in Alnylam Pharmaceuticals stock? - MSN
ALNY Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Alnylam Pharmaceuticals, Inc. $ALNY Shares Bought by ANTIPODES PARTNERS Ltd - MarketBeat
Alnylam Pharmaceuticals Adjusts Valuation Grade Amid Strong Financial Performance Indicators - Markets Mojo
A Look At Alnylam Pharmaceuticals (ALNY) Valuation As HELIOS B Data And TTR Guidance Reassure Investors - simplywall.st
ALNY Stock Price, Quote & Chart | ALNYLAM PHARMACEUTICALS INC (NASDAQ:ALNY) - ChartMill
Alnylam teams up with Viz.ai and American Heart Association to advance ATTR-CM care - MSN
Alnylam reiterates 2026 TTR sales guidance of $4.4B-$4.7B while expanding TRITON-CM enrollment to about 1,750 - MSN
Alnylam (NASDAQ: ALNY) director exercises 11,250 stock options at $70.20 - Stock Titan
Is Alnylam (ALNY) One of the Best Aggressive Growth Stocks to Buy? - Insider Monkey
Capital World Investors holds 10.9M Alnylam shares (NASDAQ: ALNY) - Stock Titan
Capital Research holds 9.47M shares of Alnylam (NASDAQ: ALNY) in 13G/A - Stock Titan
Alnylam Pharmaceuticals stock (US02005N1000): Backs TTR revenue outlook amid AMVUTTRA growth - AD HOC NEWS
5 Best Aggressive Growth Stocks to Buy According to Wall Street Analysts - Insider Monkey
Alnylam Pharmaceuticals Backs TTR Outlook as AMVUTTRA Access, Prescriber Growth Build - sharewise.com
ALNY: Strong AMVUTTRA growth, ambitious pipeline, and robust cash position drive future expansion - TradingView
Morgan Stanley Increases Price Goal on Alnylam Pharmaceuticals, Inc. (ALNY) - Insider Monkey
Alnylam Pharmaceuticals stock (US02005N1000): Q1 earnings beat and vutrisiran data - AD HOC NEWS
2.20%
2.52%
자본화:
|
볼륨(24시간):